Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expression

In Vivo

Volumn 25, Issue 5, 2011, Pages 725-732

  Rubenstein, Marvin ^a,b,c   Hollowell, Courtney M P ^c   Guinan, Patrick ^a,b,c,d  

^a Hektoen Institute for Medical Research   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Jr Hospital of Cook County   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antisense oligonucleotides; BAX; BCL 2; Caspase 3; Clusterin; Prostate cancer

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE 3; CLUSTERIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LIPOFECTIN; OLIGOS; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER INHIBITION; CELL STRAIN LNCAP; DRUG MECHANISM; PROTEIN BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 79960622296     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. www.oncogenex.ca/
2. ANTISENSE PHARMA GmbH 2011-02-02
3. Rubenstein M, Tsui P and Guinan P: Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors. Med Hypotheses 65: 905-907, 2005.
4. Rubenstein M, Tsui P and Guinan P: Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy. Methods Find Clin Pharmacol 28: 515-518, 2006. (Pubitemid 44885380)
5. Rubenstein M, Tsui P and Guinan P: Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and BCL-2 for the treatment of prostate cancer. Med Oncol 24: 372-378, 2007.
6. Rubenstein M, Tsui P and Guinan P: Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors. Comparison between combination therapies employing bispecific oligonucleotides with either rapamycin or paclitaxel. Med Oncol 26: 124-130, 2009.
7. Rubenstein M, Tsui P and Guinan P: Bispecific antisense oligonucleotides having binding sites directed against an autocrine-regulated growth pathway and BCL-2 for the treatment of prostate tumors. Med Oncol 24: 189-196, 2007. (Pubitemid 350135970)
8. Yamanaka K, Miyake H, Zangemeister-wittke U, Jansen B and Gleave M: Novel bispecific antisense oligonucleotides inhibiting both BCL-2 and Bcl-xL expression induce apoptosis and enhance chemosensitivity in human androgen-independent prostate cancer cells. Proceedings AACR 45: (online) Abstract #2930, 2004.
9. Takahara K, Muramaki M, Li D, Cox ME and Gleave ME: Insulin-like growth factor-binding protein-5 (IGFBP5) supports prostate cancer cell proliferation. J Urol 181: 184a, 2009.
10. Rubenstein M, Mirochnik Y, Bremer E, George D, Freilich L and Guinan P: Inhibitory effect of antisense oligonucleotides targeting epidermal growth factor receptor may not be related to changes in mRNA levels in human prostate carcinoma cells. Proc AACR 43: 590a, 2002.
11. Rubenstein M, Tsui P and Guinan P: A review of antisense oligonucleotides in the treatment of human disease. Drugs of the Future 29: 893-909, 2004. (Pubitemid 39531758)
12. Rubenstein M, Mirochnik Y, Chow P and Guinan P: Antisense oligonucleotide intralesional therapy of human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol 62: 194-200, 1996. (Pubitemid 26231490)
13. Rubenstein M, Mirochnik Y, Chou P and Guinan P: Growth factor deprivation therapy of hormone-insensitive prostate and breast cancers utilizing antisense oligonucleotides. Meth Find Clin Pharmacol 20: 825-831, 1998. (Pubitemid 29102373)
14. Rubenstein M, Glick R, Lichtor T, Mirochnik Y, Chou P and Guinan P: Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor. Med Oncol 75: 121-130, 2001. (Pubitemid 32929484)
15. Rubenstein M, Tsui P and Guinan P: Treatment of prostate and breast tumors employing mono- and bispecific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and BCL-2. Med Oncol 27: 592-599, 2010.
16. Rubenstein M, Tsui P and Guinan P: Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2. Med Oncol 25: 182-186, 2008.
17. Rubenstein M, Hollowell CMP and Guinan P: Inhibition of bcl-2 by antisense oligonucleotides is followed by a compensatory suppression of caspase-3 in LNCaP cells. Eur J of Clin Med Oncol 3: 1-6, 2011.
18. Rubenstein M, Hollowell C.M.P and Guinan P: In LNCaP cells enhanced expression of the androgen receptor compensates for bcl-2 suppression by antisense oligonucleotides. Ther Adv Urol 3: 73-79, 2011. DOI 10.1177/1756287211400493.
19. Rubenstein M, Hollowell CMP and Guinan P: BAX expression remains unchanged following antisense treatment directed against BCL-2. (Manuscript in Press: Medical Oncology; Published online SpringerLink date April 27, 2010).
20. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ and Tindall DJ: PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of BCL-2 expression. J Biol Chem 276: 38830-38836, 2001.
21. Salakou, S, Kardamakis D, Tsamandas AC, Zolota V, Apostolakis E, Tzelepi V, Papathanasopoul P, Bonikos DS, Papapetropoulos T, Petsas T and Dougenis D: Increased BAX .BCL-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with myasthenia gravis. In Vivo 21: 123-132, 2007. (Pubitemid 46359209)
22. Perlman H, Zhang X, Chen MW, Walsh K and Buttyan R: An elevated BAX/BCL-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death Diff 6: 48-54, 1999. (Pubitemid 29051854)
23. Yip KW, Mocanu JD, Au PY, Sleep GT, Busson D, Yeh P, Gilbert WC, O'Sullivan R, Gullane B, Bastianutto C and Liu FF: Combination BCL-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 11: 8131-8144, 2005. (Pubitemid 41698758)
24. Mu Z, Hachem P and Pollack A: Antisense BCL-2 sensitizes prostate cancer cells to radiation. Prostate 65: 331-340, 2005. (Pubitemid 41759965)
25. Rubenstein M, Anderson KM, Tsui P and Guinan P: Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer. Med Hypoth 67: 1375-1380, 2006.